Merck KGaA is returning to BioMarin Pharmaceutical Inc the rights to the Kuvan (sapropterin) drug against rare genetic disorder PKU as the diversified German group seeks to exit non-core areas to focus on cancer, immunology and neurology.
Merck KGaA Returns PKU Drugs To BioMarin To Focus On Cancer
Merck KGaA is returning to BioMarin Pharmaceutical Inc the rights to the Kuvan (sapropterin) drug against rare genetic disorder PKU as the diversified German group seeks to exit non-core areas to focus on cancer, immunology and neurology.
More from Anticancer
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.